HIPEC is “Valid” Treatment Option in CRC Peritoneal Metastases


Quantifying disease volume to help identify potential recurrence following surgery may be a helpful advance, according to Sean Dineen, MD.

There is “good evidence” supporting the use of cytoreduction with or without hyperthermic intraperitoneal chemotherapy (HIPEC) as a “valid treatment option” for patients with colorectal cancer (CRC) and peritoneal metastases, said Sean Dineen, MD.

Dineen, an associate member in the Gastrointestinal Department, section leader for Peritoneal Disease, and the program director for the Complex General Surgical Oncology Fellowship at Moffitt Cancer Center, spoke with CancerNetwork® following the 2024 Society of Surgical Oncology Annual Meeting (SSO) about advancements he hopes to see in the treatment of those with peritoneal malignancies. At the meeting, he gave a presentation discussing how to determine optimal tumor burden for using cytoreductive surgery plus HIPEC in those with CRC.

Looking ahead, Dineen said he hopes to see advances in markers of various disease volumes, which may help identify potential recurrence in patients who undergo surgery.


One area where we can be [more] effective is increasing the awareness of cytoreduction plus or minus HIPEC as a treatment option for patients with colorectal cancer and peritoneal disease. There are some data on this. Anecdotally, those of us who treat a lot of patients like this feel like patients are referred either late or are not referred at all. We can increase the word that this is a pretty valid treatment option. There’s a fair bit of debate about the role of HIPEC, the intraperitoneal chemotherapy, in what the benefit of that specific aspect of surgery is. In terms of surgery being effective, there’s quite good evidence that it is. One thing that came from that meeting was trying to think of ways to encourage typical medical oncologists to refer patients for consideration of surgery. That’s one thing.

In terms of other specific areas, we’ve talked in a couple of aspects about how to best assess the burden of disease and then how best to assess recurrence. Those are somewhat overlapping in the sense that we need or would certainly benefit from better markers of high-volume, low-volume, or moderate-volume disease. Trying to figure out better ways to quantify that would be helpful. If those same tools could then be used after surgery to help identify recurrence, those would be very helpful advances.


Dineen S. Optimal tumor burden for CRS/HIPEC in colorectal cancer. Presented at the Society of Surgical Oncology (SSO) 2024 Annual Meeting; March 20-23, 2024; Atlanta, GA.

Related Videos
Patients with NSCLC who have comorbidities or frailty may also be able to receive treatment with fewer toxicities via proton beam radiotherapy.
Terrence T. Sio, MD, MS, emphasizes multidisciplinary collaboration for treating patients with NSCLC who may require more than 1 type of therapy.
Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
D. Ross Camidge, MD, PhD, spoke about how the approval of alectinib is the beginning of multiple other approvals for patients with ALK-positive NSCLC.
Nurses should be educated on cranial nerve impairment that may affect those with multiple myeloma who receive cilta-cel, says Leslie Bennett, MSN, RN.
Treatment with cilta-cel may give patients with multiple myeloma “more time,” according to Ishmael Applewhite, BSN, RN-BC, OCN.
Nurses may need to help patients with multiple myeloma adjust to walking differently in the event of peripheral neuropathy following cilta-cel.
Administering neoadjuvant therapy to patients with colorectal cancer may help surgical oncologists attain a negative-margin resection.
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.